Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Repurposed Promise In Competitive Indication

 
• By Jung Won Shin
liver
Hanmi’s First Major Licensing Out Deal For Years • Source: Shutterstock

More from South Korea

More from Focus On Asia